MX2016014642A - Compuestos y composiciones farmaceuticas antivirales, asi como metodos de uso de los mismos. - Google Patents
Compuestos y composiciones farmaceuticas antivirales, asi como metodos de uso de los mismos.Info
- Publication number
- MX2016014642A MX2016014642A MX2016014642A MX2016014642A MX2016014642A MX 2016014642 A MX2016014642 A MX 2016014642A MX 2016014642 A MX2016014642 A MX 2016014642A MX 2016014642 A MX2016014642 A MX 2016014642A MX 2016014642 A MX2016014642 A MX 2016014642A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical compositions
- methods
- viral compounds
- compounds
- viral infection
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 230000000840 anti-viral effect Effects 0.000 title 1
- 208000036142 Viral infection Diseases 0.000 abstract 2
- 230000009385 viral infection Effects 0.000 abstract 2
- 102100037435 Antiviral innate immune response receptor RIG-I Human genes 0.000 abstract 1
- 101710127675 Antiviral innate immune response receptor RIG-I Proteins 0.000 abstract 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000005860 defense response to virus Effects 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461991418P | 2014-05-09 | 2014-05-09 | |
| US201562177900P | 2015-03-25 | 2015-03-25 | |
| PCT/US2015/030014 WO2015172099A1 (en) | 2014-05-09 | 2015-05-08 | Anti-viral compounds, pharmaceutical compositions, and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016014642A true MX2016014642A (es) | 2017-05-25 |
Family
ID=54393071
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016014642A MX2016014642A (es) | 2014-05-09 | 2015-05-08 | Compuestos y composiciones farmaceuticas antivirales, asi como metodos de uso de los mismos. |
| MX2020005187A MX2020005187A (es) | 2014-05-09 | 2016-11-08 | Compuestos y composiciones farmaceuticas antivirales, asi como metodos de uso de los mismos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020005187A MX2020005187A (es) | 2014-05-09 | 2016-11-08 | Compuestos y composiciones farmaceuticas antivirales, asi como metodos de uso de los mismos. |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US9884876B2 (OSRAM) |
| EP (1) | EP3139920A4 (OSRAM) |
| JP (1) | JP6419313B2 (OSRAM) |
| CN (1) | CN106456615B (OSRAM) |
| AU (3) | AU2015255714B2 (OSRAM) |
| CA (1) | CA2948178A1 (OSRAM) |
| MX (2) | MX2016014642A (OSRAM) |
| TW (1) | TW201623265A (OSRAM) |
| WO (1) | WO2015172099A1 (OSRAM) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018252193B2 (en) | 2017-04-14 | 2024-12-12 | Tallac Therapeutics, Inc. | Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use |
| CA3051422A1 (en) * | 2018-08-09 | 2020-02-09 | Kineta, Inc. | Activators of the retinoic acid inducible gene "rig-i" pathway and methods of use thereof |
| TW202035426A (zh) * | 2018-08-17 | 2020-10-01 | 美商奇尼塔公司 | 視黃酸誘導基因"rig-i"途徑之活化劑及其使用方法 |
| JP2022506351A (ja) * | 2018-11-02 | 2022-01-17 | アイクリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | Ｂ型肝炎ウイルス（ｈｂｖ）に対して活性を有する新規ウレア６，７－ジヒドロ－４ｈ－チアゾロ［５，４－ｃ］ピリジン |
| AU2020289560A1 (en) * | 2019-06-05 | 2021-12-23 | Emory University | Peptidomimetics for the treatment of coronavirus and picornavirus infections |
| WO2021007283A1 (en) * | 2019-07-09 | 2021-01-14 | Regents Of The University Of Minnesota | Potentiation of antiviral nucleobases as rna virus therapy |
| EP4037706A4 (en) * | 2019-10-02 | 2023-09-13 | University of Washington | Compositions and methods for treatment of hepatitis b virus infection |
| US11920136B2 (en) | 2020-02-28 | 2024-03-05 | Tallac Therapeutics, Inc. | Transglutaminase-mediated conjugation |
| WO2021198980A1 (en) | 2020-04-04 | 2021-10-07 | Pfizer Inc. | Methods of treating coronavirus disease 2019 |
| WO2021205290A1 (en) | 2020-04-05 | 2021-10-14 | Pfizer Inc. | Compounds and method of treating covid-19 |
| CN114641485A (zh) | 2020-04-05 | 2022-06-17 | 辉瑞大药厂 | 用于治疗covid-19的化合物和方法 |
| WO2021205296A1 (en) | 2020-04-05 | 2021-10-14 | Pfizer Inc. | Method of treating covid-19 |
| JP2023524271A (ja) | 2020-05-08 | 2023-06-09 | ボルト バイオセラピューティクス、インコーポレーテッド | エラスターゼ－基質ペプチドリンカーイムノコンジュゲート、及びそれらの使用 |
| CA3178994A1 (en) | 2020-05-19 | 2021-11-25 | Iyassu Sebhat | Ampk activators |
| CN113831301B (zh) * | 2020-06-08 | 2023-06-06 | 沈阳药科大学 | 苯并噻唑类衍生物及其用途 |
| JP2023531726A (ja) | 2020-06-26 | 2023-07-25 | キャリーオペ，インク． | Ａｍｐｋアクチベーター |
| US20230339930A1 (en) | 2020-07-11 | 2023-10-26 | Pfizer Inc. | Antiviral Heteroaryl Ketone Derivatives |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
| EP4228631B1 (en) * | 2020-10-15 | 2024-08-21 | Baden-Württemberg Stiftung gGmbH | Flavi-block: a pan-flavivirus inhibitor |
| CN116897155A (zh) * | 2021-02-24 | 2023-10-17 | 豪夫迈·罗氏有限公司 | 用于治疗和预防乙型肝炎病毒感染的苯并噻唑基双环[1.1.1]戊烷衍生物 |
| CN117460738A (zh) * | 2021-03-24 | 2024-01-26 | 阿纳韦克斯生命科学公司 | 冠状病毒感染的预防和治疗 |
| WO2022208262A1 (en) | 2021-03-30 | 2022-10-06 | Pfizer Inc. | Ether-linked antiviral compounds |
| TWI869780B (zh) | 2022-03-02 | 2025-01-11 | 美商輝瑞大藥廠 | 用於篩檢人類個體之呼吸疾病、監測人類個體之呼吸病況以及提供決策支援之方法及電腦化系統 |
| WO2024149990A1 (en) | 2023-01-10 | 2024-07-18 | Oxford University Innovation Limited | Nirmatrelvir analogs as 3c like protease inhibitors for treating viral infections |
| WO2024252327A1 (en) | 2023-06-09 | 2024-12-12 | Pfizer Inc. | Solid forms of n-(methoxycarbonyl)-3-methyl-l-valyl-(4 r)- n-{(1 s)-1-cyano-2-[(3 s)-2-oxopyrrolidin-3-yl]ethyl}-4-(trifluoromethyl)-l-prolinamide and solvates thereof |
| WO2025037206A1 (en) | 2023-08-11 | 2025-02-20 | Pfizer Inc. | Deuterated antiviral compounds |
| WO2025040743A1 (en) | 2023-08-22 | 2025-02-27 | Univerza V Ljubljani | Conjugated tlr7 and rig-i agonists |
| WO2025191272A1 (en) | 2024-03-13 | 2025-09-18 | Storm Therapeutics Ltd | Inhibitory compounds |
| CN119707862B (zh) * | 2025-02-24 | 2025-06-27 | 北京悦康科创医药科技股份有限公司 | 基于RLRs受体激动剂的疫苗佐剂脂质化合物、包含其的组合物及用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1024316A (en) * | 1911-07-29 | 1912-04-23 | Singer Mfg Co | Strip folding and guiding attachment for sewing-machines. |
| JPS53129036A (en) * | 1977-04-18 | 1978-11-10 | Fuji Photo Film Co Ltd | Color photographic material |
| JPH0780355B2 (ja) * | 1987-01-22 | 1995-08-30 | 富士写真フイルム株式会社 | 光学的情報記録媒体 |
| GB9923710D0 (en) | 1999-10-08 | 1999-12-08 | Proteus Molecular Design | Chemical compounds |
| WO2004078115A2 (en) * | 2003-02-28 | 2004-09-16 | Viropharma, Incorporated | Benzothiazole compounds, compositions and methods for treatment and prophylaxis of rotavirus infections and associated diseases |
| EP1680431A1 (en) * | 2003-10-17 | 2006-07-19 | Rigel Pharmaceuticals, Inc. | Benzothiazole and thiazole'5,5-b!pyridine compositions and their use as ubiquitin ligase inhibitors |
| MX2010005649A (es) * | 2007-11-21 | 2010-08-18 | Abbott Lab | Compuestos novedosos como ligandos del receptor canabinoide y sus usos. |
| US8895596B2 (en) * | 2010-02-25 | 2014-11-25 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| WO2012155352A1 (en) | 2011-05-19 | 2012-11-22 | Eli Lilly And Company | Dihydroisoxazole compounds, parasiticidal uses and formulations thereof |
| AP2014007595A0 (en) * | 2011-09-30 | 2014-04-30 | Kineta Inc | Anti-viral compounds |
| US9073946B2 (en) * | 2013-01-15 | 2015-07-07 | Kineta, Inc. | Anti-viral compounds |
| CN103193770B (zh) * | 2013-03-20 | 2015-10-28 | 中国人民解放军第二军医大学 | 取代苯并噻唑类抗真菌化合物及其制备方法与应用 |
-
2015
- 2015-05-08 EP EP15789075.7A patent/EP3139920A4/en not_active Withdrawn
- 2015-05-08 JP JP2017511565A patent/JP6419313B2/ja not_active Expired - Fee Related
- 2015-05-08 US US15/308,058 patent/US9884876B2/en not_active Expired - Fee Related
- 2015-05-08 WO PCT/US2015/030014 patent/WO2015172099A1/en not_active Ceased
- 2015-05-08 CN CN201580024136.9A patent/CN106456615B/zh not_active Expired - Fee Related
- 2015-05-08 CA CA2948178A patent/CA2948178A1/en not_active Abandoned
- 2015-05-08 TW TW104114809A patent/TW201623265A/zh unknown
- 2015-05-08 AU AU2015255714A patent/AU2015255714B2/en not_active Ceased
- 2015-05-08 MX MX2016014642A patent/MX2016014642A/es unknown
-
2016
- 2016-11-08 MX MX2020005187A patent/MX2020005187A/es unknown
-
2018
- 2018-01-31 US US15/885,333 patent/US20190002477A1/en not_active Abandoned
-
2020
- 2020-03-12 AU AU2020201815A patent/AU2020201815A1/en not_active Abandoned
- 2020-05-08 US US16/870,208 patent/US20200270274A1/en not_active Abandoned
- 2020-06-29 AU AU2020204324A patent/AU2020204324A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2948178A1 (en) | 2015-11-12 |
| MX2020005187A (es) | 2020-08-20 |
| US9884876B2 (en) | 2018-02-06 |
| CN106456615A (zh) | 2017-02-22 |
| JP6419313B2 (ja) | 2018-11-07 |
| EP3139920A1 (en) | 2017-03-15 |
| WO2015172099A1 (en) | 2015-11-12 |
| US20200270274A1 (en) | 2020-08-27 |
| CN106456615B (zh) | 2020-10-27 |
| AU2020201815A1 (en) | 2020-04-02 |
| JP2017515901A (ja) | 2017-06-15 |
| US20190002477A1 (en) | 2019-01-03 |
| AU2015255714B2 (en) | 2019-12-12 |
| EP3139920A4 (en) | 2017-11-01 |
| US20170057978A1 (en) | 2017-03-02 |
| AU2020204324A1 (en) | 2020-07-16 |
| TW201623265A (zh) | 2016-07-01 |
| AU2015255714A1 (en) | 2016-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020005187A (es) | Compuestos y composiciones farmaceuticas antivirales, asi como metodos de uso de los mismos. | |
| SMT202000716T1 (it) | Nucleosidi sostituiti, nucleotidi e loro analoghi per uso nel trattamento di infezione virale | |
| MX2022013524A (es) | Anticuerpos neutralizantes para el virus de inmunodeficiencia humana. | |
| MX2017005252A (es) | Metodos para la preparacion de ribosidos. | |
| PH12017500803A1 (en) | Anti-pd-1 antibodies | |
| MY187540A (en) | Compounds active towards bromodomains | |
| PH12015501648A1 (en) | 2-aminopyrimidine derivatives for the treatment of viral infections | |
| WO2015153889A3 (en) | Materials and methods for the treatment of latent viral infection | |
| EA201791460A1 (ru) | N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения | |
| MY169159A (en) | Piperidino-pyrimidine derivatives for the treatment of viral infections | |
| PL3174870T3 (pl) | Tieno[3,2-d]pirymidyny, furo[3,2-d]pirymidyny i pirolo[3,2- d]pirymidyny przydatne do leczenia zakażeń syncytialnym wirusem oddechowym | |
| PH12017500393A1 (en) | Pyrrolopyrimidines for use in influenza virus infection | |
| PH12016502555A1 (en) | Methods of preparing substituted nucleotide analogs | |
| EP3212658A4 (en) | 2',2'-dihalo nucleoside analogs for treatment of the flaviviridae family of viruses and cancer | |
| MX2017000312A (es) | Derivados de isoindolina para usarse en el tratamiento de una infeccion viral. | |
| EP3134423A4 (en) | 2' -disubstituted nucleoside analogs for treatment of the flaviviridae family of viruses and cancer | |
| MX2017003928A (es) | Composiciones farmaceuticas de accion prolongada. | |
| MX2017013795A (es) | Combinaciones terapeuticas de tratamientos antivirales y antiinflamatorios. | |
| PH12015502564B1 (en) | Pyridone derivatives for the treatment of viral infections and further diseases | |
| WO2014113492A3 (en) | Anti-viral compounds | |
| PH12017500817A1 (en) | Long acting pharmaceutical compositions for hepatitis c | |
| PH12017500820A1 (en) | Combination long acting compositions and methods for hepatitis c | |
| SG10201903630UA (en) | Iminosugars useful for the treatment of viral diseases | |
| TH1501007495A (th) | อนุพันธ์ไพร์โรโล [3,2-d] ไพริมิดีนสำหรับการรักษาการติดเชื้อไวรัสและโรคอื่นๆ | |
| TH1501006890A (th) | อนุพันธ์ไพริโดนสำหรับการบำบัดการติดเชื้อไวรัสและโรคอื่นเพิ่มเติม |